Among them, inhibition of acetylcholinesterase, butyrylcholinesterase, and prolyl oligopeptidase can be beneficial targets in the treatment of Alzheimer’s disease. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.